Cancer ABCs From Surviving To Thriving - How to Thrive with Cancer

Using The Genomic Health ARV-7 Test When You Are Taking Xtandi, Zytiga or Erleada

July 03, 2019
Cancer ABCs From Surviving To Thriving - How to Thrive with Cancer
Using The Genomic Health ARV-7 Test When You Are Taking Xtandi, Zytiga or Erleada
Chapters
Cancer ABCs From Surviving To Thriving - How to Thrive with Cancer
Using The Genomic Health ARV-7 Test When You Are Taking Xtandi, Zytiga or Erleada
Jul 03, 2019
Joel Nowak from Cancer ABCs and Anson Tharayanil from Genomic Health
A podcast about the Genomic Health test, The Oncotype DX ARV-7 Nucleus Detect Test, to determine a man with castrate resistant metastatic prostate cancer sensitivity to Xtandi, Zytiga and Erleada.
Show Notes

In this podcast Anson Tharayanil, a Meical Science Liaison from Genomic Health, Inc. talks with Joel Nowak about their test, the Oncotype DX ARV-7 Nucleus Detect Test for men with castrate resistant metastatic prostate cancer.  

The test is used to determine if the second line hormone therapies like Xtandi, Zytiga and Erleada will be an effective treatment for men who have the diagnosis of prostate cancer that has left the gland (if they have metastases) and are no longer responding to the first line hormone (ADT) treatments like Lupron, Eligard, Prostap and Casodex.  

Initially, Anson gives an explanation about what is castrate resistant metastatic prostate cancer so that everyone can clearly understand the disease process that happens as prostate cancer progresses.  Afterwards, he describes how the Oncotype DX ARV-7 Nucleus Detect Test works so that you can know if you are a candidate for any of the new second line hormone therapy drugs (Zytiga, Xtandi and Erleada). 

Anson also describes how it might be possible to re-sensitive some men who have stopped responding to thee drugs.